Umbilical Cord Blood Transplant With Added Sugar and Chemotherapy and Radiation Therapy in Treating Patients With Leukemia or Lymphoma

• Status: Recruiting
• Trial end date: 2022-10-31

Summary

This phase II trial studies how well an umbilical cord blood transplant with added sugar works with chemotherapy and radiation therapy in treating patients with leukemia or lymphoma. Giving chemotherapy and total-body irradiation before a donor umbilical cord blood transplant helps stop the growth of cells in the bone marrow, including normal blood-forming cells (stem cells) and cancer cells. When the healthy stem cells from a donor are infused into the patient they may help the patient's bone marrow make stem cells, red blood cells, white blood cells, and platelets. The umbilical cord blood cells will be grown ("expanded") on a special layer of cells collected from the bone marrow of healthy volunteers in a laboratory. A type of sugar will also be added to the cells in the laboratory that may help the transplant to "take" faster.

• Phase: Phase 2

Details

• Lead Sponsor: M.D. Anderson Cancer Center
• Collaborators: Mesoblast, Inc.; National Cancer Institute (NCI)
• Treatments: Antibodies; Antibodies, Monoclonal; Antilymphocyte Serum; Antineoplastic Agents, Immunological; Busulfan; Clofarabine; Cyclophosphamide; Fludarabine; Fludarabine phosphate; Immunoglobulins; Lenograstim; Mechlorethamine; Melphalan; Mesna; Mycophenolate mofetil; Mycophenolic Acid; Nitrogen Mustard Compounds; Rituximab; Tacrolimus; Thymoglobulin; Vidarabine